

WO9947140

**Title:  
TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS**

**Abstract:**

In a preferred embodiment, a method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to the surface or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/445</b>	A1	(11) International Publication Number: <b>WO 99/47140</b> (43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: <b>PCT/US99/04412</b>		(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 1 March 1999 (01.03.99)		
(30) Priority Data: 60/078,307 17 March 1998 (17.03.98) US		Published <i>With international search report.</i>
(71)(72) Applicant and Inventor: MARGOLIN, Solomon, B. [US/US]; 6723 Desco Drive, Dallas, TX 75225 (US).		
(74) Agent: CROZIER, John, H.; 1934 Huntington Turnpike, Trumbull, CT 06611-5116 (US).		

(54) Title: TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS

(57) Abstract

In a preferred embodiment, a method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to the surface or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

Description

Topical Antiseptic Compositions and Methods

5 Technical Field

The present invention relates to antiseptic compositions and, more particularly, to an ointment, cream, or foam containing pirfenidone and/or related compounds, for disinfecting the skin.

10

Background Art

A large number of various disinfecting preparations are known. When hygienic purposes are concerned, disinfection becomes rather difficult, 15 because it is necessary to reconcile an efficient antiseptic effect with demonstrable harmlessness with respect to the skin. Many such known disinfecting preparations cause adverse reactions when applied to the skin, such as skin irritation, even though the 20 preparations may have satisfactory antiseptic properties.

Accordingly, it is a principal object of the present invention to provide new disinfectant compositions and methods of application which are 25 harmless to the skin, while exerting a marked killing action on microorganisms which develop on or in the outer layers of the dermis.

It is a further object of the invention to provide such a disinfectant composition as an ointment, cream, 30 or foam formed in an aqueous dispersion of one or more substances, the water of the dispersion being dissolved or emulsified therein and carrying suitable fatty solvents and an active ingredient.

-2-

It is an additional object of the invention to provide such a disinfectant composition that is self-sanitizing, that is, the composition causes the complete destruction of bacteria and fungi after the composition 5 has been deliberately inoculated with contaminating infectious microbes.

It is another object of the invention to provide such a disinfectant composition that can be utilized as an antimicrobial disinfectant for various inanimate 10 objects.

It is yet a further object of the invention to provide such a disinfectant that is long lasting because of the persistence of the active agent on the surface of the skin.

15 It is yet a an additional object of the invention to provide such a disinfectant that penetrates into the several outer layer of the dermis.

It is yet another object of the invention to provide such a disinfectant that is harmless with 20 respect to the skin.

Other objects of the present invention, as well as particular features, elements, and advantages thereof, will be elucidated in, or be apparent from, the following description and the accompanying drawing 25 figures.

#### Disclosure of Invention

The present invention achieves the above objects, among others, by providing, in a preferred embodiment, a 30 method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to said surface or layers a pharmaceutical substance including an effective amount 35 of one or more 2-(1H) pyridone compound(s).

-3-

Best Mode for Carrying Out the Invention

The present invention relates to medical compositions and methods for the novel antiseptic topical treatment of microbial (bacteria, fungi, viruses) on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, which composition comprises pirfenidone (5-methyl-1-phenyl-2-(1H) pyridone) and/or related compounds in an appropriate formulation of a pharmaceutical topical ointment, cream, lotion, or solution.

Furthermore, the present invention is directed to a non-irritating, emollient, germicidal pharmaceutical composition. This composition affords a method of using the formulations as antiseptics for untoward skin conditions such as a dermal wound, bruise, or microbial infections, as well as for other damaged external body surface tissues, by safely penetrating outer layers of skin and related tissues or structures. In addition, the antimicrobial data indicate the compositions to be self-sanitizing, since the composition can cause marked elimination or complete destruction of bacteria and fungi after the composition has been deliberately inoculated with infectious microbes. The composition also can be utilized as an antimicrobial disinfectant for various inanimate objects. As formulated, the composition is stable for many months at temperatures of 25 degrees Centigrade or less.

The invention provides an ointment, cream, or foam formed in an aqueous dispersion of one or more active substances, the water of the dispersion being dissolved or emulsified therein and carrying suitable fatty solvents and the active ingredient(s), pirfenidone and/or related compounds. The preferred concentration of the active ingredient(s) is from about 5 to about 10 weight percent.

-4-

The composition of the present invention provides an effective microbial sanitizer, disinfectant, and barrier in one composition. The antimicrobial effects are very marked as evidenced by the several tests set forth below.

By adding suitable ingredients to the active compound(s), such as glycerine, natural colorants, surfactants, emulsifiers, and oils, it is possible to produce antiseptic products which are presented as 10 antiseptic lotions, antiseptic solutions, lotions, antiseptic ointments, and antiseptic foams. In the case of antiseptic ointments, creams, lotions, and solutions, the cited bactericidal, fungicidal, and virucidal effects are recognizable within minutes. The antiseptic 15 products and their method of manufacture are illustrated below.

The ingredients of the compositions include USP products: white petrolatum, propylene glycol 400, and stearyl alcohol, for example, all appropriately 20 dissolved and emulsified into purified distilled water. In order to illustrate the general dermatological composition of the present invention, a base composition of the following can be prepared:

25        MODIFIED USP HYDROPHILIC OINTMENT (5.0% PIRFENIDONE)

	<u>Ingredient</u>	<u>Percent by Weight</u>
	Pirfenidone (USAN) Powder	5.0
	Propylene Glycol 400 USP	23.5
	Sterile Distilled Water	30.5
30	Stearyl Alcohol USP	20.5
	White Petrolatum USP	<u>20.5</u>
		TOTAL: 100.0

MODIFIED USP HYDROPHILIC OINTMENT (10.0% PIRFENIDONE)

	<u>Ingredient</u>	<u>Percent by Weight</u>
	Pirfenidone (USAN) Powder	10.0
	Propylene Glycol 400 USP	14.3
	Sterile Distilled Water	41.7

-5-

Stearyl Alcohol USP	17.0
White Petrolatum USP	<u>17.0</u>
TOTAL: 100.0	

5        It is important to mix and melt the aqueous components (pirfenidone, propylene glycol 400, and water), heating to about 70 degrees Centigrade independently from the lipophilic phases (stearyl alcohol and white petrolatum) which also must be heated  
10      to about 70 degrees Centigrade to facilitate mixing and melting. When each phase has been adequately mixed and melted, they are combined and cooled with rapid stirring, until the mixture congeals into a fluffy, white ointment. The temperature of the ointment when it  
15      congeals will be about 40-45 degrees Centigrade.  
(Failure to adequately mix by vigorous stirring during the chilling step will result in the separation of the two solvent phases, and the emulsifying properties of the formulation will have been lost.)

20       A critical feature of the compositions of this invention is the chemical stability of the active ingredient(s), pirfenidone and/or related compounds. Crystalline pirfenidone is stable at room temperature (i.e., 25 degrees Centigrade) for more than five years.  
25       The formulations described above are stable for two years or longer at 25 degrees Centigrade (room temperature), based upon chemical assays and upon physical characteristics (color, plasticity, active ingredient dispersion and suspension).

30       The formulations described above have demonstrated their efficacy against the following microorganisms:

Escherichia coli  
Staphylococcus aureus  
Bacillus subtilis  
35      Pseudomonas aeruginosa  
Proteus vulgaris  
Trichophyton mentagrophytes

-6-

Candida albicans  
Aspergillus niger  
Influenza virus  
Coxsakie virus  
5 Herpes virus  
Papilloma virus

10

15

20

25

30

35

-7-

TABLE I  
PRELIMINARY ANTIMICROBIAL TEST OF PIRFENIDONE

		Pirfenidone Concentrations, wt.%					
		2.0	0.0*	5.0	0.0*	10.0	0.0*
5		GROWTH SCORES (0 TO 10)***					
<b>BACTERIA:</b>							
	Proteus vulgaris	-**	-	0	10	0	10
	Escherichia coli	-	-	0	10	0	10
	Pseudomonas aeruginosa	1	10	0	10	0	10
10	Bacillus subtilis	-	-	0	10	0	10
	Staphylococcus aureus	-	-	0	10	0	10
<b>FUNGI:</b>							
	Candida albicans	-	-	2	10	0	10
15	Aspergillus niger	-	-	0	10	0	10
	Trychophyton						
	mentagrophytes	-	-	2	10	0	10
<hr/>							
	* Control.						
20	** Not tested.						
	*** 1=very slight						
	2=slight						
	3=slight to moderate						
	4=moderate						
25	<hr/> 10=total plate growth (maximal growth)						
	(End of Table I)						

-8-

METHODS FOR MEASURING ANTIMICROBIAL ACTIVITY  
IN TOPICAL PREPARATIONS FOR TABLE I:

TESTING DISINFECTING ACTIVITY

5       A nutritive broth is prepared by dissolving a commercial nutritive substance in 1000 ml. of sterile distilled water. The solution is heated to 100 degrees Centigrade and poured into sterile Petri dishes under sterile conditions. After cooling and solidifying, the  
10      gels are then kept at 37 degrees Centigrade for the specified number of hours or days.

Using the modified USP hydrophilic ointment with and without pirfenidone, the procedure outlined below was followed to determine bacterial and fungal counts.

15      This procedure is based on that described in the booklet "microbiological Examination of Topical Drugs and Cosmetics," published by the Division of Microbiology, United States Food and Drug Administration, January 7, 1969.

20

Bacteria Plate Count:

Ten (10) grams of sample is aseptically measured into 90 ml. diluent (Butterfield's phosphate diluent with azolectin and Tween 80) to make a 10 (1 pwr) dilution. Decimal dilutions from 10 (1 pwr) to 10 (4 pwr) are made using 90 ml. dilution blanks of Butterfield's phosphate diluent. Duplicate plates from each of the above dilutions are made following directions of AOAC, 11th ed., 1970, pp 842-843, 41.015, except for the use of Trypticase Soy Agar (42-45 degrees Centigrade) in place of plate count agar.

One ml. of each dilution is placed into a Petri dish and Trypticase Soy Agar is added within 15 minutes from the time of original dilution. Plates were  
35      incubated for 48 hours at 35 degrees Centigrade, and duplicate plates for each dilution with colony counts in the range of 30 to 300 per plate are counted and

-9-

averaged. Counts are reported as aerobic plate count per gram of sample.

Fungi Plate Count:

5        Decimal dilutions as described above for the aerobic bacteria plate count are prepared. Aliquots of 1.0 ml. of each dilution are delivered to each of quadruplicate (4) plates. Plates are poured with 20-25 ml. of "Sabouraud's Dextrose Agar. Two plates are  
10      incubated at 37 degrees Centigrade, and other two plates are incubated at room temperature (26 degrees Centigrade) for seven days. Counts of duplicate plates are averaged and reported, in each case, as counts per gram of sample.

15

20

25

30

35

-10-

TABLE II  
ADDITIONAL PIRFENIDONE ANTI-MICROBIAL PILOT TESTS

Test # 1:

5        A 2.0% solution of pirfenidone was prepared in nutrient broth, and then was inoculated with *Pseudomonas aeruginosa*. After 48 hours of incubation at 37 degrees Centigrade, the nutrient broth failed to evidence any growth. Then a standard loopful from this pirfenidone  
10      treated broth was streaked on Tryptic Soy Agar (Difco) and incubated for 5 days at 37 degrees Centigrade; no growth of *Pseudomonas aeruginosa* was seen.

Test # 2:

15      A 5.0% solution of pirfenidone in Tryptic Soy Agar (Difco) was formulated. Pirfenidone was dissolved in hot agar. When permitted to cool to room temperature (26 degrees Centigrade), pirfenidone became a suspension in a uniform slightly opaque manner throughout the  
20      agar. At 10.0% of pirfenidone in Tryptic Soy Agar, the drug formed a uniformly opaque suspension in the agar. Growth was completely inhibited at both concentrations of the following organisms:

25

30

35

-11-

Antiseptic Effect Against Bacteria:

Agar inoculated with the following bacteria, and  
incubated at 37 degrees Centigrade:

	Escherichia coli	ATCC	#11229
5	Proteus vulgaris	ATCC	# 6538
	Bacillus subtilis	ATCC	#19659
	Staphylococcus aureus	ATCC	#13315
	Pseudomonas aeruginosa	ATCC	#15442

10 Antiseptic Effect Against Fungi:

Agar inoculated with the following fungi and  
incubated at 26 degrees Centigrade:

	Trichophyton mentagrophytes	ATCC	# 9129
	Candida albicans	ATCC	#10259
15	Aspergillus niger	ATCC	# 9642

(End of Table II)

20

25

30

35

-12-

TABLE III  
CHALLENGE TESTS

Challenge tests were conducted of pirfenidone  
5 against microbial inoculations into: (a) nutrient broth,  
and (b) 5.0% or 10.0% pirfenidone ointments (modified  
USP hydrophilic ointment). A *Pseudomonas aeruginosa*  
inoculation into broth served as a positive control.

The bacterial mixture for inoculation consisted  
10 of:

*Escherichia coli*  
*Proteus vulgaris*  
*Bacillus subtilis*  
*Staphylococcus aureus*  
15 *Pseudomonas aeruginosa*

The fungal mixture for inoculating consisted of:

*Trichophyton mentagrophytes*  
*Candida albicans*  
*Aspergillus niger*

20 After seven days, the respective cultures were  
plated out to determine the number of microbes present.  
The results as compared with the baseline number of  
microbes present when the cultures were inoculated  
follows:

25

30

35

-13-

		Pseudomonas <u>(Positive Control)</u>	Mixed Bacteria	Mixed Fungi
		<u>Microbes per gm. of Sample (After 7 days)</u>		
<b>Baseline (day 1)</b>				
5	(No Pirfenidone)	52 million (100.0%)	23 million (100.0%)	240,000 (100.0%)
	2.0% Broth Solution (Pirfenidone)	<100 (0.0%)	530,000 (2.3%)	2,000 (0.08%)
10	5.0% Ointment (Pirfenidone)	510,000 (0.01%)	57,000 (0.02%)	350 (0.002%)
	10.0% Ointment (Pirfenidone)	2,600 (0.0001%)	70,000 (0.03%)	<10 (0.0%)
15	(End of Table III)			

20

25

30

35

-14-

TABLE IV  
CHALLENGE EXPERIMENTS

Challenge experiments were conducted over four weeks for pirfenidone ointment against mixed microbial inoculations into: (a) nutrient broth, and (b) 5.0% or 10.0% pirfenidone ointments. A *Pseudomonas aeruginosa* inoculation into broth served as a positive control.

The bacterial mixture for inoculation consisted 10 of:

	Escherichia coli	ATCC	#11229
	Proteus vulgaris	ATCC	# 6538
	Bacillus subtilis	ATCC	#19659
	Staphylococcus aureus	ATCC	#13315
15	<i>Pseudomonas aeruginosa</i>	ATCC	#15442

The fungal mixture for inoculation consisted of:

Trichophyton mentagrophytes	ATCC	# 9129
Candida albicans	ATCC	#10259
Aspergillus niger	ATCC	# 9642

20 At weekly intervals for four weeks, the respective cultures were plated out into Petri dishes to determine the number of microbes present. The results as compared with the baseline number of microbes present when the cultures were first inoculated follow:

25

30

35

-15-

		Pseudomonas <u>(Positive Control)</u>	Mixed Bacteria	Mixed Funqi
		<b>Baseline (day 1)</b>		
		(No Pirfenidone) 52 million	23 million	240,000
5		(100.0%)	(100.0%)	(100.0%)
		<b>2.0% Broth Solution (Control)</b>		
		<b>(With Pirfenidone)</b>		
10		After 1 week: <100 (0.0%)	590,000 (2.3%)	<100 (0.0%)
		After 2 weeks: <10 (0.0%)	690,000 (3.0%)	<10 (0.0%)
		After 3 weeks: <10 (0.0%)	1,100,000 (4.4%)	<10 (0.0%)
15		After 4 weeks: <10 (0.0%)	510,000 (2.2%)	<10 (0.0%)
		<b>5.0% Ointment</b>		
		<b>(Pirfenidone)</b>		
20		After 1 week: 510,000 (0.98%)	57,000 (0.25%)	<100 (0.0%)
		After 2 weeks: 1,480,000 (2.8%)	68,000 (0.30%)	<10 (0.0%)
		After 3 weeks: 790,000 (1.5%)	65,000 (0.28%)	<100 (0.0%)
25		After 4 weeks: 180,000 (0.34%)	44,000 (0.19%)	<10 (0.0%)
		<b>10.0% Ointment</b>		
30		<b>(Pirfenidone)</b>		
		After 1 week: 260,000 (0.50%)	70,000 (0.30%)	<10 (0.0%)
		After 2 weeks: 2,060,000 (3.9%)	166,000 (0.71%)	<10 (0.0%)
35		After 3 weeks: 1,240,000 (2.2%)	280,000 (1.20%)	<10 (0.0%)
		After 4 weeks: 1,020,000	131,000	<10

-16-

(2.0%)

(0.57%)

(0.0%)

(End of Table IV)

5

10

15

20

25

30

35

-17-

The data (Tables I, II, III, and IV) demonstrate that compositions (solutions or ointments) containing pirfenidone at concentrations of 2.0% to 10.0% are distinctly disinfective against aerobic pathogenic 5 bacteria and fungi in a manner typical of antiseptics, and their efficacy increases within a range of increasing concentrations. Disinfectant effects are greatly reduced at concentrations lower than 1.5%.

10 **SAFETY**

**Primary Skin Irritation Tests:**

According to several primary skin (abraded and non-abraded) irritant test in albino rabbits, the primary 15 irritation index is well below 0.5, and therefore the tests samples of the respective compositions cannot be classified as positive skin irritants.

**Acute Topical Irritation/Local Toxicity Tests:**

20 **(1) Primary Rabbit Acute Eye Irritation Test**  
**for 2.0% Pirfenidone Solution**

Pirfenidone, as a 2.0% sterile aqueous solution was applied to the eye corneas of six albino rabbits, and failed to cause any irritation as evidenced by the 25 absence of hyperemia, edema, eye discomfort, or chemotaxis (Draize method). The eyes were carefully examined at 1.0 minutes, 30 minutes, and 3 hours after applying the solution, and then repeatedly examined for 10 days after the application of the pirfenidone 30 solution (0.1 ml. per eye).

**(2) Primary Rabbit Acute Eye Irritation Test**  
**for 10.0% Pirfenidone Modified USP Hydrophilic Ointment**

Modified USP hydrophilic ointment containing 10.0% pirfenidone was applied to the right eye corneas of 6 35 albino rabbits and did not cause any irritation as evidenced by the absence of hyperemia, edema, eye discomfort, or chemotaxis (Draize method). The eyes were carefully examined at 1, 3, 8, 24, and 48 hours and

-18-

carefully re-examined daily for 10 days after the application of the ointment (100 milligrams per eye).

(3) Subacute (21 days) Dermal Local and Systemic Toxicity in Albino Rabbits

5        Graded amounts of modified USP hydrophilic ointment containing 10.0% pirfenidone repeatedly was topically applied to the dorsal aspect of the clipped abraded or non-abraded skin of the back. The graded amounts of ointment were 200 mg/kg/day, 2000 mg/kg/day, 10 and 5000 mg/kg/day. The controls received 5000 mg/kg/day of the placebo vehicle ointment. The rabbits were observed carefully each day for signs of any irritation to the skin (erythema, edema, necrosis, etc.) and were scored according to the method of Draize. They 15 also were observed for any alterations in general appearance and behavior.

No evidence of irritation of the skin (abraded or non-abraded) was seen in any of the groups. No effect was seen at any dose level upon general appearance, 20 behavior, body weight gain, or upon any of the detailed hematological and blood chemistry values, or upon urinalyses. In addition, gross and histopathological examination of several vital organs and tissues failed to show any drug-related changes. In this subacute 25 rabbit experiment, the data indicates that 5000 mg/kg/day of a 10.0% pirfenidone ointment for 21 days is devoid of any demonstrable local or systemic toxicity.

ACUTE ORAL TOXICITY OF 10.0% PIRFENIDONE

30        HYDROPHILIC OINTMENT IN RODENTS

The acute toxicity of the composition cited, determined in female and male rats and/or mice, exceeds 5000 mg/kg/day when administered orally, or topically.

In fasted albino mice, the oral LD<sub>50</sub> was 35 calculated to be 11,000 +/- 1,100 mg/kg of body weight. This was determined according to the mortality found over 14 days following administration of the six graded doses to groups of 7 mice per dose level. In fasted

-19-

albino rats, the oral LD50 was greater than 10,000 mg/kg body weight, since no deaths and no signs of toxicity occurred.

5       The following are illustrative examples of the various end use compositions of the invention.

EXAMPLE 1

A modified USP hydrophilic ointment composition  
10 was prepared containing, however, 10.0% of pirfenidone. The composition was applied topically to patients who recently experienced lacerations which had become infected. No systemic antimicrobial agents were used. Remission of the infection occurred within 24 hours and  
15 complete healing occurred within 5 to 10 days.

EXAMPLE 2

Modified USP hydrophilic ointment composition was prepared containing 10.0% of pirfenidone. The  
20 composition was applied topically daily to the toenails of patients with longstanding (several years) fungus infections of the toenails. These infections had been treated repeatedly with many types of antifungal agents without success. The pirfenidone ointment completely  
25 cleared these fungus infections in 3 to 12 weeks, and the lesions did not recur on 2-year follow-ups. Pirfenidone is unusual in its ability to penetrate into the collagenous matrix of the toenail, and then into the dermal layers underneath the toenail.

30       The cited hydrophilic ointment also is very effective in successfully treating, as well as preventing, the fungus infections characteristic of "athlete's foot".

35

EXAMPLE 3

The composition was prepared and applied topically to patients having a bacterial infection and inflamed local rash at a rate of three times daily. Relief of

-20-

discomfort occurred within 1 to 3 hours, and complete healing along with clearing of the rash, was seen after 5 to 7 days.

5

EXAMPLE 4

The above cited hydrophilic composition was applied to patients having debraded skin due to a scalding burn. Improvement included reduced irritation within one hour and a marked remission was seen in 24 10 hours after commencement of treatment and subsequently no infections occurred. The composition was applied 3 times daily until full remission was achieved. Complete remission was present after 5 to 7 days.

15

EXAMPLE 5

In vivo with patients. Intact or ruptured blisters and sharp soreness of "cold sores" (herpes virus #1) on lips and adjacent oral regions of skin were terminated readily after topical daily applications of 20 10.0% pirfenidone hydrophilic ointment, and the lesions were gone in 5 to 10 days.

In vivo with patients. Various dermal facial warts (papilloma viruses) were eliminated by repeated daily applications of 10.0% pirfenidone hydrophilic 25 ointment, and the warts were gone in 3 to 6 weeks after initiating treatment with the ointment depending on the size of the wart.

EXAMPLE 6

30 As a barrier ointment or cream, pirfenidone hydrophilic ointment prevents the re-infection of previously treated microbial lesions, and has been repeatedly been observed in patients with various dermal cuts, traumatic injuries, and also in bed-ridden 35 patients with "bed sores".

-21-

EXAMPLE 7

An example of a modified USP hydrophilic ointment (10.0% pirfenidone) is as follows:

5	Pirfenidone (USAN) Powder	100 gms
	Propylene Glycol 400 USP	143 ml (143 gms)
	Sterile Distilled Water	417 ml (417 gms)
	Stearyl Alcohol USP	170 gms
	White Petrolatum	<u>170 gms</u>
	TOTAL:	1000 gms

10

EXAMPLE 8

An example of a vanishing cream formula (5.0% pirfenidone) is as follows:


15	Pirfenidone (USAN) Powder	50 gms
	Stearic Acid USP	30 gms
	Emplilan SE 40*	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
20	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
	TOTAL:	1000 gms

\* Trademark

25 Methods of preparation of pirfenidone and related compounds are described in US Patent No. 3,839,346, issued October 1, 1974, to Gadekar, and titled N-SUBSTITUTED PYRIDONES AND GENERAL METHOD FOR PREPARING PYRIDONES.

30 In addition to pirfenidone, 2-(1H) pyridone compounds having the following general structural formula have been shown to, or are expected to, have the same antiseptic properties, when applied in the concentrations and vehicles as described above with  
35 respect to pirfenidone:

-22-



5

where: R1 = alkyl group (CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, etc.); A is phenyl, thienyl, etc., or other aryl group. The alternate is for R3 to be the site of substitution of the alkyl group with R1 remaining as a hydrogen; R2 and R4 are, in every 10 circumstance, hydrogens.

10

Examples of the additional 2-(1H) pyridones include:

- 5-Methyl-1-(3-nitrophenyl)-2-(1H) pyridone
- 5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone
- 5-Methyl-1-p-tolyl-2-(1H) pyridone
- 5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H) pyridone
- 1-(4'Chlorophenyl)-5-Methyl-2-(1H) pyridone
- 5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone
- 5-Methyl-1-(1'naphthyl)-2-(1H) pyridone
- 3-Methyl-1-phenyl-2-(1H) pyridone
- 3-Ethyl-1-phenyl-2-(1H) pyridone
- 6-Methyl-1-phenyl-2-(1H) pyridone
- 3,6-Dimethyl-1-phenyl-2-(1H) pyridone
- 5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone
- 1-(2'-Furyl)-5-Methyl-2-(1H) pyridone
- 5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone
- 5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone
- 5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone
- 5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone
- 1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone
- 5-Ethyl-1-phenyl-2-(1H) pyridone
- 1-Phenyl-2-(1H) pyridone
- 1-(4'-Nitrophenyl)-2-(1H) pyridone
- 1,3-Diphenyl-2-(1H) pyridone

20

25

30

35

-23-

1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone

1,3-Diphenyl-5-methyl-2-(1H) pyridone

3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)  
pyridone, and

5 5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)  
pyridone.

It will thus be seen that the objects set forth above, among those elucidated in, or made apparent from, the preceding description, are efficiently attained and, 10 since certain changes may be made in the above compositions and methods without departing from the scope of the invention, it is intended that all matter contained in the above description.

It is also to be understood that the following 15 claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.

20

25

30

35

-24-

Claims


1. An antiseptic topical pharmaceutical substance, comprising: an effective amount of one or 5 more 2-(1H) pyridone compound(s) in a suitable carrier medium.

2. An antiseptic topical pharmaceutical substance, as defined in Claim 1, wherein: said one or 10 more 2-(1H) pyridone compounds(s) is (are) present in an ointment, cream, or foam.

3. An antiseptic topical pharmaceutical substance, as defined in Claim 2, wherein: said one or 15 more 2-(1H) pyridone compounds(s) is (are) present in an aqueous dispersion of one or more substances.

4. An antiseptic topical pharmaceutical substance, as defined in Claim 1, wherein: said one or 20 more 2-(1H) pyridone compounds are present in a concentration of from about two weight percent to about 10 weight percent.

5. An antiseptic topical pharmaceutical substance, as defined in Claim 1, wherein: said one or 25 more 2-(1H) pyridone compounds have the following general structural formula:



30

where: R1 = alkyl group (CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, etc.); A is phenyl, thiienyl, etc., or other aryl group; alternatively, R3 is the site of substitution of said alkyl group with R1 35 remaining as a hydrogen; and R2 and R4 are, in every circumstance, hydrogens.

-25-

6. An antiseptic topical pharmaceutical substance, as defined in Claim 5, wherein: said one or more 2-(1H) pyridone compounds are selected from the group consisting of:

5        5-Methyl-1-phenyl-2-(1H) pyridone  
          5-Methyl-1-(3-nitrophenyl-2)-(1H) pyridone  
          5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone  
          5-Methyl-1-p-tolyl-2-(1H) pyridone  
          5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H)  
10      pyridone  
          1-(4'Chlorophenyl)-5-Methyl-2-(1H) pyridone  
          5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone  
          5-Methyl-1-(1'naphthyl)-2-(1H) pyridone  
          3-Methyl-1-phenyl-2-(1H) pyridone  
15      3-Ethyl-1-phenyl-2-(1H) pyridone  
          6-Methyl-1-phenyl-2-(1H) pyridone  
          3,6-Dimethyl-1-phenyl-2-(1H) pyridone  
          5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone  
          1-(2'-Furyl)-5-Methyl-2-(1H) pyridone  
20      5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone  
          5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone  
          5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone  
          5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone  
          5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone  
25      5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone  
          5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone  
          1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone  
          5-Ethyl-1-phenyl-2-(1H) pyridone  
          1-Phenyl-2-(1H) pyridone  
30      1-(4'-Nitrophenyl)-2-(1H) pyridone  
          1,3-Diphenyl-2-(1H) pyridone  
          1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone  
          1,3-Diphenyl-5-methyl-2-(1H) pyridone  
          3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)  
35      pyridone, and  
          5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)  
          pyridone.

-26-

7. An antiseptic topical compound, as defined in  
Claim 1, wherein: said pharmaceutical substance has the  
following composition, in weight percent:

	Pirfenidone (USAN) Powder	5.0
5	Propylene Glycol 400 USP	23.5
	Sterile Distilled Water	30.5
	Stearyl Alcohol USP	20.5
	White Petrolatum USP	<u>20.5</u>
		TOTAL: 100.0

10

8. An antiseptic topical compound, as defined in  
Claim 1, wherein: said pharmaceutical substance has the  
following composition, in weight percent:

	Pirfenidone (USAN) Powder	10.0
15	Propylene Glycol 400 USP	14.3
	Sterile Distilled Water	41.7
	Stearyl Alcohol USP	17.0
	White Petrolatum USP	<u>17.0</u>
		TOTAL: 100.0

20

9. An antiseptic topical compound, as defined in  
Claim 1, wherein: said pharmaceutical substance has the  
following composition, in weight percent:

	Pirfenidone (USAN) Powder	50 gms
25	Stearic Acid USP	30 gms
	Emplilan SE 40*	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
30	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
		TOTAL: 1000 gms

-27-


10. A method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to said surface  
5 or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

11. A method, as defined in Claim 10, further  
10 comprising: providing said one or more 2-(1H) pyridone compound(s) present in an ointment, cream, or foam.

12. A method, as defined in Claim 11, further comprising: providing said one or more 2-(1H) pyridone  
15 compound(s) present in an aqueous dispersion of one or more substances.

13. A method, as defined in Claim 10, further comprising: providing said one or more 2-(1H) pyridone  
20 compound(s) present in a concentration of from about two weight percent to about 10 weight percent.

14. A method, as defined in Claim 10, wherein:  
said one or more 2-(1H) pyridone compound(s) have the  
25 following general structural formula:



30 where: R<sub>1</sub> = alkyl group (CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, etc.); A is phenyl, thienyl, etc., or other aryl group; alternatively, R<sub>3</sub> is the site of substitution of said alkyl group with R<sub>1</sub> remaining as a hydrogen; and R<sub>2</sub> and R<sub>4</sub> are, in every  
35 circumstance, hydrogens.

-28-

15. A method, as defined in Claim 14, further comprising: providing said one or more 2-(1H) pyridone compound(s) selected from the group consisting of:

5-Methyl-1-phenyl-2-(1H) pyridone

5-Methyl-1-(3-nitrophenyl-2)-(1H) pyridone

5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone

5-Methyl-1-p-tolyl-2-(1H) pyridone

5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H)  
pyridone

10 1-(4'Chlorophenyl)-5-Methyl-2-(1H) pyridone

5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone

5-Methyl-1-(1'naphthyl)-2-(1H) pyridone

3-Methyl-1-phenyl-2-(1H) pyridone

3-Ethyl-1-phenyl-2-(1H) pyridone

15 6-Methyl-1-phenyl-2-(1H) pyridone

3,6-Dimethyl-1-phenyl-2-(1H) pyridone

5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone

1-(2'-Furyl)-5-Methyl-2-(1H) pyridone

5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone

20 5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone

5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone

5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone

5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone

5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone

25 5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone

1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone

5-Ethyl-1-phenyl-2-(1H) pyridone

1-Phenyl-2-(1H) pyridone

1-(4'-Nitrophenyl)-2-(1H) pyridone

30 1,3-Diphenyl-2-(1H) pyridone

1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone

1,3-Diphenyl-5-methyl-2-(1H) pyridone

3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)  
pyridone, and

35 5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)  
pyridone.

-29-

16. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	5.0
5	Propylene Glycol 400 USP	23.5
	Sterile Distilled Water	30.5
	Stearyl Alcohol USP	20.5
	White Petrolatum USP	<u>20.5</u>
		TOTAL: 100.0

10

17. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	10.0
15	Propylene Glycol 400 USP	14.3
	Sterile Distilled Water	41.7
	Stearyl Alcohol USP	17.0
	White Petrolatum USP	<u>17.0</u>
		TOTAL: 100.0

20

18. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	50 gms
25	Stearic Acid USP	30 gms
	Emplilan SE 40	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
30	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
		TOTAL: 1000 gms

## INTERNATIONAL SEARCH REPORT

<p>International application No. PCT/US99/04412</p>
---

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 31/445

US CL :514/315, 327

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/315, 327

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE, APS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,974,281 A (GADEKAR) 10 August 1976, see the entire document.	1-18
X	US 5,179,098 A (CLOUGH et al.) 12 January 1993, see the entire document.	1-18
X	US 5,314,892 A (CLOUGH et al.) 24 May 1994, see the entire document.	1-18

Further documents are listed in the continuation of Box C.

See patent family annex.

*A*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

05 MAY 1999

Date of mailing of the international search report

14 MAY 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KEVIN E. WEDDINGTON

Telephone No. (703) 308-1235

JOYCE BRIDGERS  
PARALEGAL SPECIALIST  
CHEMICAL MATRIX

*Gab G*